Episode 11.2 Rethinking VBAC Risk and a Lot More!

We unpack new studies that reshape how we counsel on VBAC after short intervals, update what we tell BRCA carriers about estrogen therapy, and explore how self-collected HPV tests can reduce screening gaps. We also question surgical marketing, workforce trends, and the shaky evidence behind aspirin dosing for preeclampsia.• Short interpregnancy interval as a VBAC risk factor, not a contraindication• Absolute uterine rupture rates in spontaneous vs induced labor• Estrogen therapy in BRCA carriers and treated gyn cancers• Cervical screening overuse and underscreening in insured populations• Self-collected HPV testing intervals and access benefits• OB-GYN workforce shortages and rural distribution gaps• Endometriosis surgery indications versus fertility claims• Robotics versus laparoscopy outcomes and training priorities• Aspirin dose trials, lack of placebo arms, and abruption signals• Reading statistics correctly and demanding better editorial standards0:00 Setting The Agenda: New Studies0:40 Short Interval Pregnancy And VBAC Risk3:10 Quantifying Uterine Rupture By Spacing8:10 Induction, Augmentation, And Rupture Math9:40 HRT In BRCA Carriers: New Evidence13:05 Estrogen After Gyn Cancers: Practice Gaps17:40 Cervical Screening: Overuse And Underscreening22:30 Self-Collected HPV Testing Guidance27:00 OB-GYN Shortages And Distribution33:20 Endometriosis Surgery And Fertility Claims41:20 Robotics Vs Laparoscopy: Outcomes And Training47:20 Aspirin Dosing For Preeclampsia: No Signal55:30 Interpreting Stats And Editorial Standards59:20 Closing Notes And Next StepsBe sure to check out thinking about obgyn.com for more information, and be sure to follow us on InstagramFollow us on Instagram @thinkingaboutobgyn.